Mizuho Medy Co.,Ltd. (4595.T)
JPY 1485.0
(0.54%)
JPY 1485.0
(0.54%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.87 Billion JPY | -4.08% |
| 2022 | 2.99 Billion JPY | 1.43% |
| 2021 | 2.95 Billion JPY | 26.08% |
| 2020 | 2.34 Billion JPY | -27.44% |
| 2019 | 3.22 Billion JPY | 3.94% |
| 2018 | 3.1 Billion JPY | 10.58% |
| 2017 | 2.8 Billion JPY | 20.28% |
| 2016 | 2.33 Billion JPY | 18.31% |
| 2015 | 1.97 Billion JPY | 3.41% |
| 2014 | 1.9 Billion JPY | 0.94% |
| 2013 | 1.89 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 731 Million JPY | 3.98% |
| 2024 Q1 | 703 Million JPY | -12.9% |
| 2023 Q4 | 807.14 Million JPY | 5.47% |
| 2023 Q2 | 672.4 Million JPY | -0.72% |
| 2023 Q3 | 765.25 Million JPY | 13.81% |
| 2023 FY | 2.87 Billion JPY | -4.08% |
| 2023 Q1 | 677.25 Million JPY | -20.67% |
| 2022 Q2 | 726.06 Million JPY | 15.59% |
| 2022 Q3 | 787.96 Million JPY | 8.53% |
| 2022 Q4 | 853.66 Million JPY | 8.34% |
| 2022 FY | 2.99 Billion JPY | 1.43% |
| 2022 Q1 | 628.16 Million JPY | -21.85% |
| 2021 Q4 | 803.82 Million JPY | 2.65% |
| 2021 Q3 | 783.04 Million JPY | 6.23% |
| 2021 Q2 | 737.14 Million JPY | 17.09% |
| 2021 FY | 2.95 Billion JPY | 26.08% |
| 2021 Q1 | 629.53 Million JPY | 2.56% |
| 2020 Q4 | 613.81 Million JPY | 6.56% |
| 2020 Q3 | 575.99 Million JPY | 24.07% |
| 2020 Q2 | 464.24 Million JPY | -32.57% |
| 2020 Q1 | 688.5 Million JPY | -28.53% |
| 2020 FY | 2.34 Billion JPY | -27.44% |
| 2019 Q2 | 616.07 Million JPY | -27.54% |
| 2019 FY | 3.22 Billion JPY | 3.94% |
| 2019 Q4 | 963.32 Million JPY | 20.63% |
| 2019 Q3 | 798.57 Million JPY | 29.62% |
| 2019 Q1 | 850.25 Million JPY | -7.66% |
| 2018 FY | 3.1 Billion JPY | 10.58% |
| 2018 Q3 | 633.48 Million JPY | 6.28% |
| 2018 Q1 | 955.47 Million JPY | 10.85% |
| 2018 Q2 | 596.07 Million JPY | -37.61% |
| 2018 Q4 | 920.75 Million JPY | 45.35% |
| 2017 Q3 | 580.91 Million JPY | -0.09% |
| 2017 FY | 2.8 Billion JPY | 20.28% |
| 2017 Q1 | 784.35 Million JPY | 58.26% |
| 2017 Q4 | 861.97 Million JPY | 48.38% |
| 2017 Q2 | 581.43 Million JPY | -25.87% |
| 2016 Q3 | 516.87 Million JPY | -2.57% |
| 2016 Q4 | 495.6 Million JPY | -4.12% |
| 2016 Q1 | 792.18 Million JPY | 130.74% |
| 2016 FY | 2.33 Billion JPY | 18.31% |
| 2016 Q2 | 530.53 Million JPY | -33.03% |
| 2015 FY | 1.97 Billion JPY | 3.41% |
| 2015 Q4 | 343.32 Million JPY | 0.0% |
| 2014 FY | 1.9 Billion JPY | 0.94% |
| 2013 FY | 1.89 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 93.415% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.89% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.47% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 98.546% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 23.087% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 95.621% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 90.099% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.461% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 45.594% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 95.633% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 93.789% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 75.126% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 65.091% |
| Tsumura & Co. | 48.8 Billion JPY | 94.111% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 91.376% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 85.291% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 95.491% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 77.295% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 92.898% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 93.67% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 30.87% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 51.661% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 44.976% |
| MedRx Co., Ltd | 959 Million JPY | -199.659% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -94.697% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -21.22% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 88.108% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 91.89% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -290.887% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 97.121% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -27.309% |